4-Bromo-2,3-difluorobenzaldehyde | CAS:644985-24-0

We serve 4-Bromo-2,3-difluorobenzaldehyde CAS:644985-24-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-2,3-difluorobenzaldehyde

Chemical Name:4-Bromo-2,3-difluorobenzaldehyde
CAS.NO:644985-24-0
Synonyms:2,3-Difluoro-4-bromobenzaldehyde;
Molecular Formula:C7H3BrF2O
Molecular Weight:220.99900
 
Physical and Chemical Properties:
Density:1.758;
Boiling point:239.859oC;
Flash point:98.864oC;
 
Specification:
Appearance:White to off-white chunks or crystalline powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of liquid crystal material



Contact us for information like 4-Bromo-2,3-difluorobenzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-Difluoro-4-bromobenzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-Difluoro-4-bromobenzaldehyde Use and application,4-Bromo-2,3-difluorobenzaldehyde technical grade,usp/ep/jp grade.


Related News: The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”2-Cyano-4-fluorobenzoic acid manufacturer The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”6-Chlorohex-1-ene supplier An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.5-nitro-2,3-dihydro-1-benzofuran vendor An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.